Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading

Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at Jones Trading to a “strong-buy” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a $24.00 target price on the biopharmaceutical company’s stock. Jones Trading’s target price would indicate a potential upside of 125.99% from the stock’s previous close.

Several other research analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Theravance Biopharma Trading Up 0.2%

TBPH traded up $0.02 during trading hours on Tuesday, hitting $10.62. 162,054 shares of the company’s stock were exchanged, compared to its average volume of 274,739. The firm has a market cap of $531.00 million, a P/E ratio of -9.00 and a beta of -0.09. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.82. The firm has a 50 day moving average of $9.70 and a 200 day moving average of $9.46.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. The business had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. As a group, research analysts expect that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the transaction, the senior vice president now owns 336,918 shares of the company’s stock, valued at $3,706,098. This represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of institutional investors have recently bought and sold shares of TBPH. Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma in the 4th quarter valued at about $25,000. GAMMA Investing LLC boosted its holdings in Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 3,281 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Theravance Biopharma in the fourth quarter valued at approximately $69,000. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma in the fourth quarter valued at approximately $103,000. Finally, AQR Capital Management LLC acquired a new stake in Theravance Biopharma during the first quarter worth approximately $101,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.